PHVS
Pharvaris NV
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
pharvaris is a preclinical stage company focused on bringing an oral bradykinin b2 receptor antagonist to patients for use as an alternative to injected therapies for hereditary angioedema (hae) and other b2 receptor-mediated indications. the company reunites the core team responsible for the discovery and approval of the hae treatment icatibant. with novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.
Market Cap: 1.34 Billion
Primary Exchange: NASDAQ
Website: pharvaris.com
Shares Outstanding: 52.1 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.0
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 69 trading days
From: 2023-09-19 To: 2023-12-05
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|